Choksi Laboratories has approved the preferential allotment of convertible equity warrants to its promoters, raising up to ₹6.19 crore. The Board of Directors finalized the proposal during a meeting held on September 19, 2026, and scheduled an Extra-Ordinary General Meeting (EGM) for shareholder approval on October 17, 2026.

The company will issue up to 3,50,000 warrants to three promoter group entities: Mr. Sunil Choksi, Ms. Himika Choksi, and Mrs. Stela Choksi. Each warrant is priced at ₹177 and is fully convertible into one equity share of face value ₹10. The pricing adheres to Regulation 165 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, based on the relevant date of September 17, 2026.

Allotment Details

The proceeds from the issue will be utilized for general corporate purposes, subject to shareholder approval. The payment structure requires 25% of the warrant issue price to be paid at subscription, with the remaining 75% payable upon exercise.

The post-issue shareholding pattern assumes full conversion of all warrants. Mr. Sunil Choksi’s stake is set to increase from 7.51% to 9.89%, while Ms. Himika Choksi’s holding will rise significantly from 0.01% to 1.38%.

Regulatory Compliance and Timeline

The approval was disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The warrants have a tenure of 18 months from the date of allotment. Unexercised warrants will lapse, and the amounts paid by holders will be forfeited by the company.

CS Surabhi Agrawal has been appointed as the scrutinizer for the e-voting process during the EGM, which will be conducted via Video Conferencing or Other Audio-Visual Means. The Board meeting commenced at 11:30 am and concluded at 3:50 pm at the company’s registered office in Indore.

Choksi Laboratories confirmed its 33rd Annual General Meeting (AGM) will be held on September 18, 2026. The company has also dispatched physical letters to shareholders who have not registered their email addresses, providing direct web links to access the annual report and AGM notice.

The communication, issued under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, clarifies that while electronic copies of the FY26 annual report were sent to registered members, those without valid emails received physical intimation. This ensures compliance with Regulation 36(1)(b), which mandates alternative communication methods for unregistered shareholders.

Financial Performance

Choksi Laboratories reported a 29% increase in net profit after tax (PAT) to ₹196.43 lakh for FY26, compared to ₹152.33 lakh in the previous year. The growth was supported by a 10.4% rise in total revenue to ₹4,621.93 lakh and an exceptional gain of ₹75.30 lakh from the sale of a Mumbai property.

The company issued its 33rd Annual Report and AGM notice on August 25, 2026, confirming the meeting date as September 18, 2026. This corrects the previously communicated date of August 21, 2026. The meeting will be conducted via Video Conferencing or Other Audio Visual Means, with the registered office in Indore serving as the deemed venue.

Revenue from operations stood at ₹4,600.59 lakh in FY26, up from ₹4,178.23 lakh in FY25. Profit before tax (PBT) was ₹319.46 lakh, including the exceptional item. Excluding this one-time gain, operational PBT was ₹244.16 lakh, compared to ₹215.33 lakh in FY25.

The improvement in financial performance was attributed to higher business volumes, better operational efficiencies, and effective resource utilization. No dividend was recommended for the year due to fund requirements for operations.

Key Operational Developments

The company faced a ransomware cyberattack on May 22, 2025, which temporarily disrupted operations and access to financial data. Critical data was recovered by May 31, 2025, using secured off-site backups. The incident delayed the approval of audited results for Q4FY25 and FY25, leading to a penalty from the stock exchange for delayed disclosures. The company has since enhanced its cybersecurity protocols.

Additionally, Choksi Laboratories changed its Registrar and Share Transfer Agent from MUFG Intime Private Limited to Ankit Consultancy Private Limited, effective August 3, 2026.

Agenda Items

Shareholders will transact the following business at the AGM:

• Approve audited financial results for the year ended March 31, 2026.
• Reappoint Mr. Sunil Choksi as a director, who retires by rotation.
• Reappoint Ms. Himika Choksi as a Whole-Time Director for five years.

Key Dates

The register of members will remain closed from September 11, 2026, to September 18, 2026.

Director Reappointment Details

The board seeks approval for the reappointment of Ms. Himika Choksi as Whole-Time Director from April 1, 2027, to March 31, 2032. Her monthly salary is set between ₹4,00,000 and ₹5,00,000, subject to annual increments of ₹25,000.

Prakhar Dubey, Company Secretary and Compliance Officer, signed the communication addressed to the General Manager of the Corporate Relationship Department at The Bombay Stock Exchange Limited.